1Massie B, Shah N. Evolving trends in the epidemiological factors of failure: Rationale for preventive strategies and comprehensive disease maaagement[J]. Am Heart J ,1997,133:703-712.
2Li RK, Yau TM, Sakai T, et al. Cell therapy to repair broken heart[J].Can J Catdiol, 1998,14(5):735-744.
3Koh GY, Soonpaa MH, Klug MG, et al. Long- term survival of AT- 1 cardiomyocyte grafts in syngeneic myocardium[J]. Am J Physiol, 1993,264:H1727 - 1733.
4Reinecke H, Zhang M, Bartosek T, Murry CE. Survival, integration, and differentiation fo cardiomyocyte grafts: a study in normal and injured rat hearts[J]. Circulation, 1999,100(2) : 193 - 202.
5Li RK, Weisel RD, Mickle DA, et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction[ J]. J Thorac Cardiovasc Surg, 2000,119(1):62-68.
6Min JY, Yang YK, Converso KL, et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats[J]. J Appl Physiol ,2002,92:288 - 296.
7Talor DA, Atkins 87,, hungspreugs P, et al. Regenerating function myocardium: improved performance after skeletal myoblast transplantation[J]. J Nat Med, 1998, 4(8):929-933.
8Orlic D, Kajstura J, C, himenti S, et al. Bone marrow cells regenerate infarcted myocardium[J]. Nature, 2001,410(6829) :701 - 5.
9Fukuda K. Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering[J]. Artif Organs, 2001,25(3) : 187 - 93.
10Hakuno D, Fukuda K, Makino S, et al. Bone marrow-derived regenerated cardiomyocytes ( CMG cells) express functional adrenergic and muscarinic receptors[J]. Circulation, 2002, 105(3) :380 - 386.
2Simon T,Mary-Krause M,Funck-Brentano C,et al.Bisoprolodose-response relationship in patients with congestiveheart failure:a subgroup analysis in the cardiacinsufficiency bisoprolol study (CIBIS Ⅱ).Eur Heart J,2003,24:552-559.
3Pitt B,Poole-Wilson PA,Segal R,et al.Effect of losartan compared with captopril on mortality in patients withsymptomatic heat failure:randomised trial-the Losartan Heart Failure Survival Study ELITE Ⅱ.Lancet,2000,355:1582-1587.
4Carson P,Tognoni G,Cohn JN.Effect of Valsartan on hospitalization:reaults from Val-HeFT.J Card Faii,2003,9:164-171.
5Pfeifer MA,Swedberg K,Granger CB,et al.Effects of candesartan on mortlity and morbidity in patients with chronic heart failure:the CHARM-Overall programme.Lancet,2003,362:759-766.
6Trifonov IR.Efficacy of an aldasterone receptorblocke replerenone in high risk survivors of acute myocardialinfarction with signs of heart failure:results of EPHESUS.Kardiologiia,2003,43:71-72.
7Marchioli R,Barzi F,Bomba E,et al.Early protectionagainst sudden death by n-3 polyunsaturated fatty acidsafier myocardial infarction:time-course analysis of the results of the Gruppo Italiano per to Studio dellaSopravvivenza nell lnfarto Miocardico (GISSI)-Prevenzione.Circulation,2002,105:1897-1903.
9Strauer BE,Brehm M,Zeus T,et aL Repair of infracted myocardium by autologous intrscoronary mononuclear bone marrow cell transplantation in humans[J].Circulation,2002,106(15):1913-1918.
